Original ArticleQuality of Life after Growth Hormone Therapy and Induced Puberty in Women with Turner Syndrome
Section snippets
Subjects
All young women with TS who had participated in 2 earlier GH trials were invited to participate in an HRQoL evaluation. The 2 earlier trials were a dose-response GH trial (DRS) and a frequent-response GH trial (FRS) to investigate the effects of long-term GH therapy, given in different dosages and at varying frequencies (see below). To be eligible, a woman had to have discontinued GH treatment for at least 6 months and to be able to fill in the questionnaires. Forty-nine women agreed to
Results
Table I presents the clinical characteristics of the 49 women with TS who participated in the HRQoL evaluation. The average height of 160.7 (6.5) cm is −1.2 (1.1) SDS lower than the normal Dutch references22 and 2.2 (1.0) SDS higher than North European untreated women with TS.23 The mean age at onset of puberty was 12.9 years, compared with 10.8 years in the normal population.7, 24 The progression through puberty, defined as the time intervals from breast stages B2 to B3, B2 to B4, and B2 to
Additional Data
Of the women with TS, 26% had a low SES level, 34% had an intermediate SES level, and 40% had a high SES level, not significantly different from the SES levels in the normal population (ie, 33% low, 34% intermediate, and 33% high).20
Table IV gives data for subjective measures reported by the TS patients and their parents. Four of the women with TS and 2 of the parents did not return the questionnaire. The 3 patients who were not happy with their height would have liked to be taller. Of the 17
Discussion
The women with TS reported higher HRQoL scores in the domains “social functioning” and “role limitations due to emotional health problems.” This means that women with TS felt less restricted in social contacts and/or daily life due to their physical health or emotional problems than the reference population. The reported results of better HRQoL in social functioning in the women with TS is remarkable; earlier data indicated that women with TS scored significantly lower on social acceptance
References (36)
- et al.
Translation, validation, and norming of the Dutch language version of the SF-36 health survey in community and chronic disease populations
J Clin Epidemiol
(1998) - et al.
Developmental changes in motor function in girls with Turner syndrome
Pediatr Neurol
(1996) - et al.
Integrating response shift into health-related quality of life research: a theoretical model
Soc Sci Med
(1999) Listening to respondents: a qualitative assessment of the Short-Form 36 health status questionnaire
Soc Sci Med
(2002)- et al.
Impact of infertility on quality of life, marital adjustment, and sexual function
Urology
(2004) - et al.
Fertility concerns and sexual behavior in adolescent girls with polycystic ovary syndrome: implications for quality of life
J Pediatr Adolesc Gynecol
(2003) - et al.
Short stature and psychosocial assessment
Acta Paediatr Suppl
(1995) - et al.
A longitudinal study of pubertal timing and extreme body change behaviors among adolescent boys and girls
Adolescence
(2004) - et al.
Normalization of height in girls with Turner syndrome after long-term growth hormone treatment: results of a randomized dose-response trial
J Clin Endocrinol Metab
(1999) - et al.
Final height in girls with Turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens
J Clin Endocrinol Metab
(2003)
Growth hormone and low-dose estrogen in Turner syndrome: results of a United States multicenter trial to near-final height
J Clin Endocrinol Metab
Adult height after GH therapy in 188 Ullrich-Turner syndrome patients: results of the German IGLU Follow-up Study 2001
Eur J Endocrinol
Results of estrogen treatment on uterine dimensions in Turner syndrome
Horm Res
Psychosocial development in adolescents with Turner syndrome
J Dev Behav Pediatr
Self-concept and behavior in adolescent girls with Turner syndrome: potential estrogen effects
J Clin Endocrinol Metab
Behavioral phenotype in children with Turner syndrome
J Pediatr Psychol
Middle-aged women with Turner's syndrome: medical status, hormonal treatment and social life
Acta Endocrinol (Copenh)
Psychosocial and sexual functioning in women with Turner syndrome
Clin Genet
Cited by (73)
The influence of psychosocial and sexual wellbeing on quality of life in women with differences of sexual development
2021, Comprehensive PsychoneuroendocrinologyCitation Excerpt :Studies of women with other forms of DSD suggests a reduced to similar QOL to the general public [19,20]. In women with TS, satisfaction with height and breast development were found to influence the QOL positively [21], whereas another study observed that height did not influence QOL and otological difficulties had a negative impact on QOL [22]. For women with CAH, one study found older age, hirsutism and hypertension to reduce global QOL, whereas the degree of virilization influenced the physical QOL negatively and the psychological QOL decreased with increasing age at genital surgery [23].
Psychosocial well-being and quality of life in women with Turner syndrome
2020, PsychoneuroendocrinologyEmotional state, cognitive functioning and quality of life of adult women with Turner syndrome in Lithuania
2019, Growth Hormone and IGF ResearchCitation Excerpt :In our study Lithuanian adult TS women had median height 151.7 cm, being approximately 11–12 cm less than 50th percentile (163.0 cm) of the National Standards of Lithuania [20]. Height gain from GH treatment in TS patients was found not to be associated with QoL scores, however, low QoL being related to the degree of short stature, although this can vary considerably and is dependent on the individual attitudes of patients [5]. Health-related QoL was shown to be worse in adult TS women than in general population and in age-matched control women in physical functioning domains, but not in psychological [26].
Psychosocial Characteristics of Women with a Delayed Diagnosis of Turner Syndrome
2018, Journal of PediatricsNeuropsychological and mental health concerns in a multicenter clinical sample of youth with turner syndrome
2023, American Journal of Medical Genetics, Part A
The growth hormone trial was supported by Novo Nordisk A/S, Bagsvard, Denmark.